会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 91. 发明申请
    • METHOD FOR PRODUCTION OF HEPARIN AND HEPARAN SULFATE
    • 生产HEPARIN和HEPARAN SULFATE的方法
    • WO2016172766A1
    • 2016-11-03
    • PCT/AU2016/050301
    • 2016-04-28
    • NEWSOUTH INNOVATIONS PTY LIMITED
    • WHITELOCK, John M.LORD, Megan S.
    • C12N15/12C12N5/10C12N5/22A61K38/17A61K38/36C07K14/435
    • C08B37/0075A61K31/727A61K38/00C07K14/4725C07K2319/02C07K2319/20C08B37/0003C12N2510/00C12N2510/02C12P19/26C12P21/005
    • This present disclosure relates to a method of producing a proteoglycan having anticoagulant activity, comprising of and providing a cell transfected with a recombinant nucleic acid encoding a core protein having one or more glycosaminoglycan attachment sites; and incubating the cell under conditions to promote the production of a proteoglycan comprising the core protein linked to heparin and/or HS and optionally other glycosaminoglycan chains, and to heparin or heparan sulphate isolated from such proteoglycans that have significant anti- coagulant activity. The invention also relates to a recombinant proteoglycan comprising a core protein and heparin and/or heparan sulfate, to a cell capable of producing a proteoglycan comprising the core protein and heparin and/or heparan sulfate, and to a method of treating or preventing blood coagulation, or a condition associated with blood coagulation, using the recombinant proteoglycan comprising a core protein and heparin and/or heparan sulfate and/or the heparin and/or heparan sulfate isolated from such proteoglycans.
    • 本公开涉及生产具有抗凝活性的蛋白多糖的方法,其包含并提供用编码具有一个或多个糖胺聚糖附着位点的核心蛋白质的重组核酸转染的细胞; 并在条件下孵育细胞以促进包含与肝素和/或HS和任选的其它糖胺聚糖链连接的核心蛋白质的蛋白聚糖的产生,以及从具有显着抗凝血活性的蛋白聚糖分离的肝素或肝素硫酸肝素。 本发明还涉及包含核心蛋白和肝素和/或硫酸乙酰肝素的重组蛋白聚糖到能够产生包含核心蛋白和肝素和/或硫酸乙酰肝素的蛋白聚糖的细胞,以及治疗或预防血液凝固的方法 或与凝血相关的病症,使用包含从蛋白多糖分离的核心蛋白和肝素和/或硫酸乙酰肝素和/或肝素和/或硫酸肝素的重组蛋白多糖。
    • 98. 发明申请
    • NEW PHARMACEUTICAL COMPOSITIONS AND THEIR USE FOR THE TREATMENT OF AUTOIMMUNE DISORDERS
    • 新药物组合物及其治疗自身免疫疾病的使用
    • WO2015136108A1
    • 2015-09-17
    • PCT/EP2015/055371
    • 2015-03-13
    • UNIVERSITE JOSEPH FOURIER
    • HUARD, BertrandLALIVE, Patrice
    • A61K38/17
    • A61K38/191A61K9/0019A61K38/395C07K14/47C07K14/525C07K2319/20C07K2319/30
    • The present invention relates to a pharmaceutical composition wherein the active substance comprises or consists in: -a protein comprising the sequence SEQ ID NO: 1, representing the APRIL protein, -or any derived protein, which is derived from protein of sequence SEQ ID NO: by substitution, removal or addition of one or more amino-acids, provided it allows the binding of the said derived protein to an astrocyte and/or CSPG, -or any homologous protein, the sequence of which has a percentage of identity of at least approximately 70 %, and in particular 85 % with said sequence SEQ ID NO: 1, provided it allows the binding of the said homologous protein to an 1 astrocyte and/or CSPG, or any fragment of the protein of sequence SEQ ID NO: 1, provided it allows the binding of the said fragment to an astrocyte and/or CSPG, in association with an acceptable pharmaceutical vehicle. 20 (no figures)
    • 本发明涉及一种药物组合物,其中活性物质包含或由以下组成: - 包含代表APRIL蛋白的序列SEQ ID NO:1的蛋白质,或衍生自序列SEQ ID NO: :通过取代,除去或添加一种或多种氨基酸,只要其允许所述衍生的蛋白质与星形胶质细胞和/或CSPG结合,或任何同源蛋白质,其序列具有在 至少约70%,特别是所述序列SEQ ID NO:1的85%,条件是其允许所述同源蛋白与1星形胶质细胞和/或CSPG或序列SEQ ID NO:1的蛋白质的任何片段的结合。 1,只要其允许将所述片段与可接受的药物载体结合,将其与星形胶质细胞和/或CSPG结合。 20(无数字)